Synowledge Announces Record Growth in 2011; Anticipates Sustained Progress in 2012

Synowledge is a global provider of drug safety, regulatory affairs and related IT solutions to small, mid and large sized pharmaceutical and biotechnology companies. Our comprehensive outsourcing solutions combine the unique strengths of both onshore and offshore services to meet our clients' needs. End Quote

(1888PressRelease) January 11, 2012 - Synowledge, LLC, a market leader in pharmacovigilance, regulatory affairs, and related IT services for pharmaceutical, medical device, and biotechnology companies, is pleased to announce 2011 as a year of record growth, with plans to continue the momentum into 2012.

In 2011, Synowledge added over 15 clients to its list of global clientele, including key multi-year case processing partnerships with a Top 5 Biotech and a Top 25 Pharma. With a volume of over 60,000 serious and non-serious adverse events processed in 2011, Synowledge's case volumes have increased significantly and Synowledge forecasts that this growth will continue in 2012. In addition to the increased case volumes, Synowledge has advanced its aggregate reporting, signal detection, literature search, and safety system maintenance services.

As a result of significant aggregate growth, Synowledge announced the May 2011 opening of Synowledge GmbH in Frankfurt, Germany to strengthen its European project management and sales functions. Additionally, Synowledge opened a state of the art delivery & training campus in Mysore, India in October 2011. The Mysore facility provides augmented delivery functions and offers full business continuity for drug safety and IT activities at Synowledge's Bangalore Delivery Center. Moving into 2012, Synowledge has also announced plans to open an office in Japan to better serve the Asia-Pacific market.

"The combination of expanded partnerships with industry leaders, steady growth in various areas of drug safety, and our extension into regulatory affairs services solidified Synowledge's position as a market leader in 2011," says David Ingraham, Director of Strategic Accounts. "With a growing network of offices and facilities spanning three continents and clients across the globe, we are confident that 2012 will be another year of significant progress. We look forward to expanding our global footprint by continuing to provide life sciences companies with value added services that increase efficiency, productivity, and compliance with regulatory agencies, while significantly reducing costs."

About Synowledge
Synowledge is a global provider of drug safety, regulatory affairs and related IT solutions to small, mid and large sized pharmaceutical and biotechnology companies. Our comprehensive outsourcing solutions combine the unique strengths of both onshore and offshore services to meet our clients' needs. With more than 15 years of industry experience, our core team members have worked with leading pharmaceutical, biotech, medical device, and health care provider organizations. Synowledge is headquartered in Stamford, CT, USA with operation facilities located in Ohio, the United Kingdom, Germany, and India. For more information, please visit www.synowledge.com.

###

space

Other Related Press Releases